Dr Al-Lamee is a clinical trialist who tests cardiovascular practice in large multi-centre clinical research trials. She has published her research in some of the world’s highest impact scientific journals including The Lancet. She has presented her work as late breaking clinical trials in the largest international cardiovascular scientific congresses.
She leads a research team at the National Heart and Lung Institute at Imperial College London investigating many aspects of cardiac care with a predominant focus on stable coronary artery disease.
Most Impactful Research
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
The Lancet 2018
This study formed Dr Al-Lamee’s PhD. She designed, led and conducted the ORBITA trial. This was the first clinical trial to test coronary angioplasty compared to a placebo procedure in the treatment of symptoms in patients with stable coronary artery disease. She presented the results as a late breaking clinical trial at TCT in Denver in 2017.
Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease: physiology-stratified analysis of ORBITA.
Dr Al-Lamee published this secondary analysis of the ORBITA trial showing that the effect of coronary angioplasty on improving the bloody supply to patient’s hearts could be predicted by the severity of their coronary disease on baseline invasive physiological tests. She presented the results as a late breaking clinical trial in EuroPCR in Paris in 2018.
Use of the instantaneous wave-free ratio or fractional flow reserve in PCI.
New England Journal of Medicine 2017
Dr Al-Lamee helped to design and conduct this multicentre international study. This clinical trial led to the incorporation of iFR into the American and European guidelines for the assessment and treatment of coronary artery disease.